More MS news articles for Dec 2001

Defective Fas ligand production in lymphocytes from MS patients

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11742248&dopt=Abstract

Neuroreport 2001 Dec 21;12(18):4113-4116
Macchi B, Matteucci C, Nocentini U, Tacconi S, Pagnini V, Mastino A, Caltagirone C.
Departments of 1Neuroscience and 2Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Via di Tor Vergata 135 00133 Rome; 3IRCCS, Clinica S. Lucia, Rome; 4Department of Microbiological, Genetic and Molecular Sciences, University of Messina, Messina, Italy.

In the present transectional study, Fas ligand (Fas-L) levels, either in membrane or in soluble form, in cells from multiple sclerosis (MS) patients were investigated. Expression of Fas was evaluated after PHA stimulation of peripheral blood mononuclear cells from MS patients with relapsing-remitting or secondary-progressive disease, and in healthy donors.

There was statistically significant decreased expression (p = 0.001), as well as release of Fas-L, (p = 0.045) in lymphocytes from MS patients, in comparison with healthy donors.

Moreover, levels of Fas-L production were inversely correlated with the EDSS scores of patients in an highly significant way.

Impairment of Fas-L release in stimulated PBMC from MS patients might influence the ability to eliminate autoreactive clones in vivo.
 

PMID: 11742248 [PubMed - as supplied by publisher]